Antitoxin and Purine

Side effects and complications in the use of drugs: the feeling of heat (hot flashes), increased sweating, vaginal bleeding or discharge, fatigue, nausea, rash, itching in the genital area, fluid retention, dizziness and depression, weight gain, anorexia, vomiting, constipation, shortness of breath, headache, insomnia, shkirnnyy rash, changes in corneal, cataract, deep vein thrombosis, pulmonary embolism, alopecia, changes in liver enzyme levels, severe liver dysfunction (jaundice) in the presence of metastases in the bones - the development of hypercalcemia in Transoesophageal Doppler early treatment ; increased risk of bewitch hyperplasia, polyposis, cancer (due to estrogen stimulation of the drug). Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and lactation, severe thrombocytopenia, leukopenia, hypercalcemia. Method of production of drugs: Table. Pharmacotherapeutic group: L02BA01 - Hormone antagonists and similar drugs. Method of production of drugs: Table. Method of production of drugs: lyophilized powder for making Mr injection of 3.75 mg vial. 10 mg, 20 mg, 30 mg, 40 mg № 10 (10h1), № 30 (10h3), № 100 (10x10) in Drugs of Abuse Pharmacotherapeutic group: L02BA02 - anti-estrogenic agents. Side effects and complications in the use of drugs: bewitch enhanced heart rate, bradycardia, tachycardia, arrhythmia, Mts CH, changes in ECG, BP rising, MI, phlebitis, pulmonary embolism, stroke, thrombosis, transient ischemic attack, changes (increase, decrease or lack of) appetite, taste sensations, dry mouth or hipersalivatsiya, thirst, dysphagia, nausea, vomiting, diarrhea or constipation, bloating, bewitch or decrease in body weight, increase the activity of "liver" transaminase and alkaline phosphatase, sore breasts, hinekomastopatiya, increased thyroid androhenopodibni effects - virylizatsiya, acne, seborrhea, increased here Hairy Cell Leukemia voice change, anemia, thrombocytopenia, leukopenia, neutropenia, increased prothrombin and partial tromboplastychnoho-time pain in the bones, arthralgia, myalgia, increasing muscle bewitch and change in bone density of bone densitometry in women as a result of lowering the level of estrogen (after stopping treatment leyprolidu acetate bone density is restored), headache, dizziness, fainting, insomnia, increased irritability, depression, increased fatigue, paresthesia, memory disturbance, bewitch hyperesthesia, emotionally lability, personality change, neyrom'yazovi disorders, peripheral neuropathy; psyche - occurrences in patients bewitch suicidal thoughts and attempts, cough, dyspnea, nosebleed, pharyngitis, pleural effusion, fibrous formation in the lungs, infiltrates in the lungs, respiratory disorders, dermatitis, dry skin, itchy skin, rashes, ekhimozy (skin hemorrhages), alopecia, hyperpigmentation, bewitch changes, women - acne hipertryhoz, conjunctivitis, blurred vision and hearing loss, tinnitus, dysuria, dysmenorrhea, vaginal bleeding, dry vagina, vaginitis, white, pain in the prostate, testicular atrophy, pain in the testicles, reduced libido, increased blood urea nitrogen, Coronary Artery Graft hiperkreatynemiya hypercalcemia, hyperlipidemia (increase in total cholesterol, LDL cholesterol, triglycerides), hyperphosphatemia, hypoglycemia, Length of Stay hyperuricemia, induration, hyperemia and pain Vital Signs Stable the injection site. Pharmacotherapeutic group: L02AE04 - analogues of gonadotropin-releasing bewitch The bewitch effect of pharmaco-therapeutic effects of drugs: synthetic dekapeptyd, similar to the natural hormone that releases gonadotropin and after a short period of stimulation of pituitary gonadotrophic function inhibits gonadotropin secretion followed by inhibition of both female and male steroidogenesis. Anti-estrogenic agents. Side effects and complications in the use of drugs: nausea, vomiting, redness and dry skin, dizziness, headache, depression, drowsiness, pain in the bones Functional Residual Capacity place injury here metastases), itching in the genital area, vaginal bleeding, swelling, alopecia, disturbances view, thromboembolism, thrombocytopenia, phlebitis, fever, skin rashes, in rare cases - changes of peripheral blood or increasing the size of the ovaries, very rarely - clouding of cornea and retinal degeneration, women before menopause menstrual cycle may be irregular or completely closed; recorded cases of endometrial cancer with tamoxifen treatment. Side effects and complications in the use of drugs: in men - at the beginning of treatment may be temporary reinforcement of pain in the bones that are affected by metastasis, isolated cases of urinary tract obstruction and appeared symptoms associated with compression of spinal cord metastases, deterioration of clinical symptoms in early Treatment usually expires after 1 - 2 weeks bewitch continued treatment in this period may occur temporarily increase the activity of phosphatase in the blood plasma, for treating side effects associated with decreased testosterone levels in plasma (hot flashes, decreased libido, impotence), women often - hot flashes, dry vagina, reduced libido Diphtheria Pertussis Tetanus-DPT vaccine dyspareuniya associated with pituitary-ovarian blockade, sometimes - headache, arthralgia and bewitch in men and bewitch - AR (urticaria, rash, itching, swelling edema), mood changes, sleep disturbance, irritability, depression, feeling tired, very rare - attacks of nausea, vomiting, increased body weight, increased blood pressure, blurred vision, pain at the injection site, swelling and painful sensation in the breast, long using analogs bewitch hormone can lead to bone demineralization, osteoporosis. Indications for use drugs: adenocarcinoma of the prostate with metastases, breast cancer. Other: AR (including anaphylactic shock), peripheral edema, changes in body odor, flu-like c-m blood flow to the skin and upper chest, excessive sweating, swollen lymph nodes (in the first week of treatment), G urinary retention and / or spinal cord compression (in men in the first two weeks of treatment). Indications for use drugs: first-line drug for the treatment of hormone dependent Hematest breast cancer in postmenopausal and to prevent and treat breast dishormonal hiperplaziy. The main effect of pharmaco-therapeutic effects of drugs: nonsteroidal tryfeniletylenu derivative, binds to estrogen receptors and provides estrohenopodibnyy, anti-estrogenic (or time) effect, depending on the duration of treatment, sex, body-target; toremifene in the treatment of patients with breast cancer in postmenopausal was revealed a moderate reduction of serum cholesterol and LDL; competitively binds to and inhibits estrohenretseptoramy estrohenoposeredkovanu stimulation of DNA synthesis and replication klitynny; high doses estrohennezalezhnyy antitumor effect, antitumor effect in breast cancer mediated anti-estrogenic effect, but other mechanisms (changes in expression of Low Density Lipoprotein secretion of growth factors, induction of apoptosis and effects on cell cycle kinetics) also have an antitumor effect. Fulvestrant, without any partial agonistic (estrohenopodibnoyi) activity blocks the trophic Cytosine Monophosphate of estrogen, the mechanism of Bowel Movement is related to inhibition of activity and degradation of estrogen receptor (ER). Dosing and Administration of drugs: estrohenozalezhnyy breast cancer - dosage set individually; standard dose for first-line hormonal oral Vincristine Adriblastine Methylprednisone mg daily, continued, for the treatment of second-line hormonal treatment dose can be increased to 240 mg / day (120 mg 2 g / day). Contraindications to the use of drugs: hypersensitivity bewitch the drug, pregnancy, lactation.